{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:51:31Z","timestamp":1792518691717,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.trre.2013.12.004","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T18:32:30Z","timestamp":1388773950000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment"],"prefix":"10.1016","volume":"28","author":[{"given":"Karl Martin","family":"Wissing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Pipeleers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2013.12.004_bb0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","author":"Ojo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0015","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0025","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/01.CIR.0000136581.59584.0E","article-title":"C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study","volume":"110","author":"Rutter","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2013.12.004_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.1994.03520030047027","article-title":"Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991","volume":"272","author":"Kuczmarski","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2013.12.004_bb0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999\u20132004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2013.12.004_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1600-6143.2006.01629.x","article-title":"A \"weight-listing\" paradox for candidates of renal transplantation?","volume":"7","author":"Schold","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.trre.2013.12.004_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/TP.0b013e3181c518cc","article-title":"Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis","volume":"89","author":"Knight","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trre.2013.12.004_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0095","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0100","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.tp.0000286095.55685.e9","article-title":"Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia","volume":"84","author":"Ma","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0110","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trre.2013.12.004_bb0115","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1681\/ASN.2006030196","article-title":"Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?","volume":"17","author":"Di","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0120","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1681\/ASN.2005050487","article-title":"Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus","volume":"16","author":"Teutonico","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0125","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-2277.2008.00640.x","article-title":"Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation","volume":"21","author":"Roland","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0135","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1681\/ASN.2008121314","article-title":"TCF7L2 polymorphism associates with new-onset diabetes after transplantation","volume":"20","author":"Ghisdal","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0140","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0145","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2009.02752.x","article-title":"Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation","volume":"9","author":"Van Laecke","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0150","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/j.1600-6143.2008.02308.x","article-title":"Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation","volume":"8","author":"Roland","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","author":"Fraenkel","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2013.12.004_bb0160","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.tp.0000235446.50715.ef","article-title":"Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation","volume":"82","author":"Wissing","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007890-199801150-00017","article-title":"Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study","volume":"65","author":"McCune","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0175","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.V122368","article-title":"Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus","volume":"12","author":"Ligtenberg","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature05097","article-title":"Calcineurin\/NFAT signalling regulates pancreatic beta-cell growth and function","volume":"443","author":"Heit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.trre.2013.12.004_bb0195","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0200","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/ndt\/15.6.867","article-title":"Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients","volume":"15","author":"Filler","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1681\/ASN.V131221","article-title":"Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction","volume":"13","author":"Boots","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0210","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0215","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/j.1600-6143.2005.01104.x","article-title":"One-year post-transplant weight gain is a risk factor for graft loss","volume":"5","author":"Ducloux","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0220","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2006.04.078","article-title":"Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation","volume":"48","author":"Porrini","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0225","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/j.1600-6143.2004.00558.x","article-title":"Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally","volume":"4","author":"de Vries","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0230","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/TP.0b013e3181f1543c","article-title":"Association of metabolic syndrome with development of new-onset diabetes after transplantation","volume":"90","author":"Bayer","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0235","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/01.tp.0000266898.93894.3d","article-title":"Metabolic syndrome and atherosclerotic events in renal transplant recipients","volume":"83","author":"Courivaud","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0240","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/TP.0b013e3181bd06d2","article-title":"Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients","volume":"89","author":"Sharif","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0245","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-6143.2005.01198.x","article-title":"Obesity and outcome following renal transplantation","volume":"6","author":"Gore","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0250","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2011.114","article-title":"Higher recipient body mass index is associated with post-transplant delayed kidney graft function","volume":"80","author":"Molnar","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00007890-200201150-00013","article-title":"The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death","volume":"73","author":"Meier-Kriesche","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0260","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1111\/j.1600-6143.2005.01073.x","article-title":"Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients","volume":"5","author":"Armstrong","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0265","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1600-6143.2006.01672.x","article-title":"Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact","volume":"7","author":"Bosma","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0270","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1432-2277.2012.01488.x","article-title":"Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant","volume":"25","author":"Israni","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0275","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2010.03330.x","article-title":"Body mass index, waist circumference and mortality in kidney transplant recipients","volume":"10","author":"Kovesdy","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0280","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ndt\/gfm762","article-title":"The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation","volume":"23","author":"Porrini","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0285","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0290","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.00210106","article-title":"Cardiorespiratory fitness is related to physical inactivity, metabolic risk factors, and atherosclerotic burden in glucose-intolerant renal transplant recipients","volume":"1","author":"Armstrong","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0295","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.03340410","article-title":"Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients","volume":"6","author":"Zelle","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0300","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.jrn.2008.11.006","article-title":"Higher levels of physical activity are associated with a lower risk of abnormal glucose tolerance in renal transplant recipients","volume":"19","author":"Orazio","year":"2009","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.trre.2013.12.004_bb0305","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/j.1600-6143.2005.00944.x","article-title":"Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients","volume":"5","author":"van den Ham","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0310","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00007890-200004270-00013","article-title":"Relation between steroid dose, body composition and physical activity in renal transplant patients","volume":"69","author":"van den Ham","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0315","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.CIR.73.1.30","article-title":"The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity","volume":"73","author":"Jennings","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0320","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1001\/jama.283.22.2961","article-title":"Physical activity and risk of stroke in women","volume":"283","author":"Hu","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2013.12.004_bb0325","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJM199302253280804","article-title":"The association of changes in physical-activity level and other lifestyle characteristics with mortality among men","volume":"328","author":"Paffenbarger","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0330","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1001\/archinte.167.22.2453","article-title":"Physical activity recommendations and decreased risk of mortality","volume":"167","author":"Leitzmann","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0335","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2215\/CJN.01970309","article-title":"Physical activity and mortality in chronic kidney disease (NHANES III)","volume":"4","author":"Beddhu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0340","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0272-6386(03)00673-5","article-title":"Effects of exercise training on coronary heart disease risk factors in renal transplant recipients","volume":"42","author":"Painter","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0345","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00007890-200207150-00008","article-title":"A randomized trial of exercise training after renal transplantation","volume":"74","author":"Painter","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1051-2276(98)90005-X","article-title":"The effect of dietary intervention on weight gains after renal transplantation","volume":"8","author":"Patel","year":"1998","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.trre.2013.12.004_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0899-9007(98)00137-3","article-title":"Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation","volume":"15","author":"Lopes","year":"1999","journal-title":"Nutrition"},{"key":"10.1016\/j.trre.2013.12.004_bb0360","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0365","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4158\/EP.8.2.124","article-title":"Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature","volume":"8","author":"Barbaro","year":"2002","journal-title":"Endocr Pract"},{"key":"10.1016\/j.trre.2013.12.004_bb0370","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: a systematic review and meta-analysis","volume":"292","author":"Buchwald","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2013.12.004_bb0375","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/0003-4819-142-7-200504050-00013","article-title":"Meta-analysis: surgical treatment of obesity","volume":"142","author":"Maggard","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0380","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sjostrom","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0385","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sjostrom","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0390","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa066603","article-title":"Long-term mortality after gastric bypass surgery","volume":"357","author":"Adams","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0395","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/TP.0b013e31819e3f14","article-title":"Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review","volume":"87","author":"Modanlou","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0400","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1755.2003.00761.x","article-title":"Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index","volume":"63","author":"Glanton","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0405","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2007050610","article-title":"Obesity impacts access to kidney transplantation","volume":"19","author":"Segev","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0410","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1159\/000345476","article-title":"Obesity and kidney transplant candidates: how big is too big for transplantation?","volume":"36","author":"Lentine","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0415","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/ndt\/gfs406","article-title":"Transplantation in the obese: separating myth from reality","volume":"27","author":"Khwaja","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0420","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2215\/CJN.02560312","article-title":"Response to dietary oxalate after bariatric surgery","volume":"7","author":"Froeder","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0425","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.soard.2005.07.002","article-title":"Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass","volume":"1","author":"Nelson","year":"2005","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0430","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.ki.5002194","article-title":"Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery","volume":"72","author":"Sinha","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0435","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semnephrol.2008.01.009","article-title":"Nephrolithiasis after bariatric surgery for obesity","volume":"28","author":"Lieske","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0440","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.ki.5002284","article-title":"Bariatric surgery, hyperoxaluria, and nephrolithiasis: a plea for close postoperative management of risk factors","volume":"72","author":"Kleinman","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0445","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.juro.2009.02.029","article-title":"Effect of gastric bypass surgery on kidney stone disease","volume":"181","author":"Matlaga","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.trre.2013.12.004_bb0450","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1097\/01.ASN.0000099380.18995.F7","article-title":"Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured\/regenerating tubular epithelial cells in rat kidneys","volume":"14","author":"Asselman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0455","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.ASN.0000038686.17715.42","article-title":"Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a nonadherent epithelium","volume":"14","author":"Verhulst","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0460","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2215\/CJN.02940608","article-title":"Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure","volume":"3","author":"Nasr","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0465","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1093\/ndt\/gfq347","article-title":"Bariatric surgery and renal function: a precarious balance between benefit and harm","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0470","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1111\/j.1600-6143.2006.01485.x","article-title":"Acute oxalate nephropathy: a new etiology for acute renal failure following nonrenal solid organ transplantation","volume":"6","author":"Lefaucheur","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0475","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/ndt\/gfi019","article-title":"Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria","volume":"20","author":"Farese","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0480","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00007890-200105150-00030","article-title":"Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria","volume":"71","author":"Donckier","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0485","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-6143.2004.00684.x","article-title":"Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival","volume":"5","author":"Pinheiro","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0490","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0495","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0500","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation: risk assessment and management","volume":"35","author":"Ghisdal","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2013.12.004_bb0505","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/ndt\/gfm011","article-title":"Diabetes mellitus after kidney transplantation: a French multicentre observational study","volume":"22","author":"Kamar","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0510","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0515","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/TP.0b013e31821620f9","article-title":"Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients","volume":"91","author":"Yang","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0520","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/sj.ki.5000116","article-title":"The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events","volume":"69","author":"Hjelmesaeth","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0525","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2215\/CJN.04681107","article-title":"Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival","volume":"3","author":"Cole","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0530","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/01.tp.0000259617.21741.95","article-title":"Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients","volume":"83","author":"Burroughs","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0535","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0540","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0545","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0550","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2013.12.004_bb0555","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/TP.0b013e318203c25f","article-title":"New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression","volume":"91","author":"Luan","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0560","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.tp.0000173378.28790.0b","article-title":"Comparison of steroid avoidance in tacrolimus\/mycophenolate mofetil and tacrolimus\/sirolimus combination in kidney transplantation monitored by surveillance biopsy","volume":"80","author":"Anil Kumar","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0565","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/00007890-200212270-00011","article-title":"Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study","volume":"74","author":"Boots","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0570","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.TP.0000154915.20524.0A","article-title":"Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation","volume":"79","author":"Rostaing","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0575","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfr374","article-title":"Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review","volume":"27","author":"Pascual","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0580","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/TP.0b013e3181e58912","article-title":"A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation","volume":"90","author":"Pascual","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0585","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00007890-199102000-00020","article-title":"Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients","volume":"51","author":"Hricik","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0590","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients","volume":"3","author":"Woodward","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0595","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0600","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0605","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.tp.0000184842.01686.CA","article-title":"Renal graft survival and calcineurin inhibitor","volume":"80","author":"Woodward","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0610","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.TP.0000079965.62765.1A","article-title":"Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids","volume":"76","author":"Bunnapradist","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0615","first-page":"146","article-title":"Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature","volume":"21","author":"Ghisdal","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.12.004_bb0620","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.transproceed.2007.06.035","article-title":"Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation","volume":"39","author":"Ramos-Cebrian","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.12.004_bb0625","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinre.2011.03.008","article-title":"Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study","volume":"35","author":"Lorho","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.trre.2013.12.004_bb0630","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.transproceed.2004.12.085","article-title":"Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus","volume":"37","author":"Oberholzer","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.12.004_bb0635","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/lt.20634","article-title":"Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus","volume":"12","author":"Dumortier","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2013.12.004_bb0640","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0645","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0650","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0655","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/j.1600-6143.2005.00983.x","article-title":"Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation","volume":"5","author":"Fellstrom","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0660","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/01.TP.0000061602.03327.E2","article-title":"Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation","volume":"75","author":"Meier-Kriesche","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0665","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0012.2005.00359.x","article-title":"Guidelines for the treatment and management of new-onset diabetes after transplantation","volume":"19","author":"Wilkinson","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0670","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1600-6143.2011.03550.x","article-title":"Should metformin be our antiglycemic agent of choice post-transplantation?","volume":"11","author":"Sharif","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0675","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2013.12.004_bb0680","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11892-012-0346-8","article-title":"Management of post-transplant diabetes","volume":"13","author":"Therasse","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.trre.2013.12.004_bb0685","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0690","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.trre.2013.12.004_bb0695","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0700","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/TP.0b013e3182347ea4","article-title":"Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation","volume":"92","author":"Lane","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.12.004_bb0705","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0710","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.V1191735","article-title":"Explained and unexplained ischemic heart disease risk after renal transplantation","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.12.004_bb0715","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0720","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0725","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0730","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0735","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0740","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0745","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0750","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0755","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trre.2013.12.004_bb0760","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","article-title":"Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients","volume":"1","author":"Asberg","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0765","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0770","first-page":"2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001"},{"key":"10.1016\/j.trre.2013.12.004_bb0775","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trre.2013.12.004_bb0780","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trre.2013.12.004_bb0785","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?","volume":"15","author":"Broeders","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0790","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.trre.2013.12.004_bb0795","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/dc09-0621","article-title":"Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy","volume":"33","author":"Forsblom","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2013.12.004_bb0800","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)05271-5","article-title":"Effects of fenofibrate and gemfibrozil on plasma homocysteine","volume":"358","author":"Westphal","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0805","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.12.004_bb0810","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2013.12.004_bb0815","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0820","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1074\/jbc.272.6.3707","article-title":"Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells","volume":"272","author":"Ledwith","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trre.2013.12.004_bb0825","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8227(98)00107-7","article-title":"Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes","volume":"42","author":"Yoshinari","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.trre.2013.12.004_bb0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","article-title":"Combination statin-fibrate therapy: safety aspects","volume":"11","author":"Franssen","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.trre.2013.12.004_bb0835","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate ofrhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trre.2013.12.004_bb0840","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.12.004_bb0845","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0850","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2013.12.004_bb0855","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","article-title":"A retrospective analysis of ezetimibe treatment in renal transplant recipients","volume":"6","author":"Buchanan","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0860","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-6143.2005.01132.x","article-title":"Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation","volume":"6","author":"Kohnle","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0865","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0870","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trre.2013.12.004_bb0875","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.12.004_bb0880","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/ndt\/gfl095","article-title":"Renal transplant dysfunction\u2014importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality","volume":"21","author":"Soveri","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0885","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/ajt.12053","article-title":"Rate of renal graft function decline after one year is a strong predictor of all-cause mortality","volume":"13","author":"Moranne","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.12.004_bb0890","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1034\/j.1600-6143.2002.21015.x","article-title":"Death after graft loss: an important late study endpoint in kidney transplantation","volume":"2","author":"Kaplan","year":"2002","journal-title":"Am J Transplant"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X13001420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X13001420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:04:34Z","timestamp":1760630674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X13001420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":178,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0955470X13001420"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2013.12.004","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2013.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}